M. Ahdesmaki

VarDict: a novel and versatile variant caller for next-generation sequencing in cancer research

O. Hofmann, J. Barrett, J. Dry, 2016, Nucleic acids research.

A reliable method for the detection of BRCA1 and BRCA2 mutations in fixed tumour tissue utilising multiplex PCR-based targeted next generation sequencing

Shuwen Huang, S. Bhaskar, G. Ellison, 2015, BMC Clinical Pathology.

Hydroxymethylation profile of cell-free DNA is a biomarker for early colorectal cancer

Albert J. Vilella, Casper K Lumby, Jordan M. Eizenga, 2021, Scientific Reports.

Development and independent validation of a prognostic assay for stage II colon cancer using formalin-fixed paraffin-embedded tissue.

Sridhar Ramaswamy, Daniel J Sargent, Oliver F Bathe, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Rational Selection of Syngeneic Preclinical Tumor Models for Immunotherapeutic Drug Discovery

Simon J. Dovedi, D. Greenawalt, Dennis Wang, 2016, Cancer Immunology Research.

Acquired Resistance to the Mutant-Selective EGFR Inhibitor AZD9291 Is Associated with Increased Dependence on RAS Signaling in Preclinical Models.

W. Pao, P. Fisher, J. Dry, 2015, Cancer research.

PIM kinase inhibitor AZD1208 for treatment of MYC-driven prostate cancer.

S. Abdulkadir, S. Grosskurth, A. Kirschner, 2015, Journal of the National Cancer Institute.

AZD5153: A Novel Bivalent BET Bromodomain Inhibitor Highly Active against Hematologic Malignancies

G. Mills, A. Dulak, A. Rabow, 2016, Molecular Cancer Therapeutics.

Fibroblast growth factor receptor 3 (FGFR3) mutant muscle invasive bladder cancers (MIBC) are associated with low immune infiltrates

Knowles, J. Barrett, E. Harrington, 2016 .

Rational Selection of Syngeneic Preclinical Tumor Models for Immunotherapeutic Drug Discovery

D. Greenawalt, Dennis Wang, R. Sainson, 2016, Cancer Immunology Research.